Pamela Eisele

A number of Alzheimer drug trials have fallen through in the last few months, and on Tuesday, Merck & co., Inc. (NYSE: MRK) added its verubecestat to the list of inefficacious treatments. The series of failed tests have inspired questions about the amyloid hypothesis on which recent treatments...